Oculis Holding AG (NASDAQ:OCS) Given Consensus Recommendation of “Moderate Buy” by Analysts

Shares of Oculis Holding AG (NASDAQ:OCS) have been given a consensus rating of “Moderate Buy” by the ten ratings firms that are covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating and nine have given a buy rating to the company. The average 1-year price target among analysts that have covered the stock in the last year is $38.3333.

Several equities analysts recently issued reports on OCS shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Oculis in a research report on Tuesday, April 21st. Stifel Nicolaus decreased their price target on Oculis from $50.00 to $40.00 and set a “buy” rating for the company in a research note on Monday, June 1st. Robert W. Baird lowered their price target on Oculis from $49.00 to $38.00 and set an “outperform” rating on the stock in a report on Monday, June 1st. HC Wainwright reaffirmed a “buy” rating on shares of Oculis in a research report on Thursday. Finally, Wall Street Zen downgraded Oculis from a “hold” rating to a “sell” rating in a report on Saturday, March 7th.

Oculis Price Performance

Shares of Oculis stock opened at $11.09 on Wednesday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.18 and a current ratio of 5.18. The stock has a market capitalization of $643.00 million, a PE ratio of -5.21 and a beta of 0.23. Oculis has a 52-week low of $10.52 and a 52-week high of $34.47. The company has a 50-day simple moving average of $24.99 and a two-hundred day simple moving average of $24.68.

Oculis (NASDAQ:OCS) last posted its quarterly earnings results on Friday, May 8th. The company reported ($0.63) EPS for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.14). The firm had revenue of $0.26 million for the quarter, compared to analysts’ expectations of $0.25 million. Oculis had a negative net margin of 8,460.67% and a negative return on equity of 56.78%. On average, analysts anticipate that Oculis will post -2.27 EPS for the current fiscal year.

Institutional Trading of Oculis

Large investors have recently made changes to their positions in the stock. China Universal Asset Management Co. Ltd. raised its holdings in shares of Oculis by 100.0% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 2,000 shares of the company’s stock valued at $40,000 after purchasing an additional 1,000 shares during the last quarter. Aventura Private Wealth LLC purchased a new stake in Oculis in the fourth quarter worth approximately $80,000. Koshinski Asset Management Inc. bought a new stake in Oculis in the 1st quarter worth approximately $238,000. Millennium Management LLC purchased a new stake in Oculis during the 4th quarter valued at $312,000. Finally, Marshall Wace LLP purchased a new stake in Oculis during the 2nd quarter valued at $393,000. 22.30% of the stock is currently owned by institutional investors.

About Oculis

Oculis SA (NASDAQ: OCS) is a clinical-stage biopharmaceutical company focused on developing novel ophthalmic therapies designed primarily to treat retinal and neuro-ophthalmic diseases. Leveraging its proprietary technology platforms, Oculis aims to deliver therapeutic agents to the back of the eye through topical or nasal administration, potentially offering an alternative to current intravitreal injections. The company’s pipeline includes OCS-01, a topical dexamethasone formulation targeting diabetic macular edema; OCS-05, a neuroprotective candidate for acute optic neuritis and idiopathic intracranial hypertension; and OC-02, a nasal spray formulation of varenicline for dry eye disease.

Founded in 2016 and headquartered in Basel, Switzerland, Oculis operates research and development facilities across Europe and in the United States, with a presence in Cambridge, Massachusetts.